united healthcare coverage for glp 1 GLP-1 2026 Medicaid fuels US coverage of
Description
2010;34:S36S42
The future of GLP-1 research As GLP-1s continue to reshape the treatment of type 2 diabetes and obesity (along with an expanding list of potential indications), real-world evidence will be essential for optimizing their use, ensuring access, and tailoring treatments to the individual needs of patients
January 15, 2025
Coverage for Cardiovascular Disease Wegovy (semaglutide 2.4 mg injection) received FDA approval in March 2024 for reducing the risk of cardiovascular death, heart attacks, and strokes
However, when purchased directly from manufacturers outside of insurance, these medications are offered at a lower price, around $499 per month or $5988 annually
